QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
NASDAQ:MCRB

Seres Therapeutics (MCRB) Stock Price, News & Analysis

$1.23
+0.09 (+7.89%)
(As of 03/1/2024 ET)
Today's Range
$1.13
$1.24
50-Day Range
$1.02
$1.56
52-Week Range
$0.91
$6.87
Volume
2.68 million shs
Average Volume
4.69 million shs
Market Capitalization
$179.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.20

Seres Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
982.0% Upside
$13.20 Price Target
Short Interest
Bearish
10.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.14
Upright™ Environmental Score
News Sentiment
0.62mentions of Seres Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$20,371 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.98) to ($1.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.87 out of 5 stars

Medical Sector

237th out of 957 stocks

Pharmaceutical Preparations Industry

105th out of 440 stocks


MCRB stock logo

About Seres Therapeutics Stock (NASDAQ:MCRB)

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MCRB Stock Price History

MCRB Stock News Headlines

Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Seres Therapeutics Inc (MCRB)
MCRB Jan 2026 1.500 call
MCRB Jan 2026 1.500 put
See More Headlines
Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
3/01/2024
Next Earnings (Confirmed)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MCRB
Fax
N/A
Employees
431
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.20
High Stock Price Target
$25.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+982.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-250,160,000.00
Pretax Margin
-111.03%

Debt

Sales & Book Value

Annual Sales
$7.13 million
Book Value
$0.09 per share

Miscellaneous

Free Float
138,571,000
Market Cap
$177.58 million
Optionable
Optionable
Beta
2.31
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Eric D. Shaff M.B.A. (Age 48)
    President, CEO & Director
    Comp: $1.07M
  • Mr. David A. Arkowitz M.B.A. (Age 63)
    Executive VP, CFO & Head of Business Development
    Comp: $670.02k
  • Dr. Matthew R. Henn Ph.D. (Age 49)
    Executive VP & Chief Scientific Officer
    Comp: $643.83k
  • Ms. Paula A. Cloghessy SHRM-SCP (Age 52)
    SPHR, Executive VP & Chief People Officer
    Comp: $521.27k
  • Dr. Lisa von Moltke M.D. (Age 65)
    Executive VP & Chief Medical Officer
    Comp: $706.14k
  • Dr. David S. Ege Ph.D. (Age 49)
    Executive VP & Chief Technology Officer
    Comp: $142.71k
  • Mr. Carlo Tanzi Ph.D.
    Investor Relations Officer
  • Mr. Thomas J. DesRosier Esq. (Age 69)
    J.D., Chief Legal Officer, Executive VP & Secretary
    Comp: $719.55k
  • Dr. Teresa L. Young Ph.D. (Age 57)
    R.Ph., Executive VP and Chief Commercial & Strategy Officer
  • Ms. Caroline Holda
    Assistant General Counsel














MCRB Stock Analysis - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MCRB shares.
View MCRB analyst ratings
or view top-rated stocks.

What is Seres Therapeutics' stock price target for 2024?

5 Wall Street analysts have issued 12-month target prices for Seres Therapeutics' stock. Their MCRB share price targets range from $7.00 to $25.00. On average, they predict the company's share price to reach $13.20 in the next year. This suggests a possible upside of 982.0% from the stock's current price.
View analysts price targets for MCRB
or view top-rated stocks among Wall Street analysts.

How have MCRB shares performed in 2024?

Seres Therapeutics' stock was trading at $1.40 at the beginning of 2024. Since then, MCRB stock has decreased by 12.9% and is now trading at $1.22.
View the best growth stocks for 2024 here
.

When is Seres Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our MCRB earnings forecast
.

How can I listen to Seres Therapeutics' earnings call?

Seres Therapeutics will be holding an earnings conference call on Tuesday, March 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by $0.19. The biotechnology company had revenue of $126.50 million for the quarter, compared to analysts' expectations of $125.67 million. The firm's quarterly revenue was up 10441.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.70) earnings per share.

What ETF holds Seres Therapeutics' stock ?

Simplify Propel Opportunities ETF holds 550,626 shares of MCRB stock, representing 2.57% of its portfolio.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.65%), Point72 Asset Management L.P. (1.66%), Handelsbanken Fonder AB (0.85%), Northern Trust Corp (0.60%), Charles Schwab Investment Management Inc. (0.52%) and Goldman Sachs Group Inc. (0.34%). Insiders that own company stock include David Arkowitz, David S Ege, Eric D Shaff, Health Ltp Fund Ge Nutritional, Paula Cloghessy, Teresa L Young and Thomas Desrosier.
View institutional ownership trends
.

How do I buy shares of Seres Therapeutics?

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MCRB) was last updated on 3/1/2024 by MarketBeat.com Staff